YNIOS Pharma is a biotech start-up, aiming to develop new oral and parenteral treatments to treat pathologies involving inflammation and restore homeostasis.
The company is developing treatments for Systemic Inflammatory Response Syndrome (SIRS) and chronic inflammatory diseases, using a proprietary ionic compound that targets innate immune pathways.

•  Sepsis – Status Sepsis study: preliminary results
•  Chronic Inflammatory Bowel Disease – Status IBD study: ongoing